BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roozbeh F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Merat S, Wentzel H, Levi J, Hill A, Shamshirian A. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. J Antimicrob Chemother 2021;76:753-7. [PMID: 33338232 DOI: 10.1093/jac/dkaa501] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 26.0] [Reference Citation Analysis]
Number Citing Articles
1 Li J, Liu S, Shi J, Wang X, Xue Y, Zhu HJ. Tissue-Specific Proteomics Analysis of Anti-COVID-19 Nucleoside and Nucleotide Prodrug-Activating Enzymes Provides Insights into the Optimization of Prodrug Design and Pharmacotherapy Strategy. ACS Pharmacol Transl Sci 2021;4:870-87. [PMID: 33855276 DOI: 10.1021/acsptsci.1c00016] [Reference Citation Analysis]
2 Akbari A, Razmi M, Sedaghat A, Alavi Dana SMM, Amiri M, Halvani AM, Yazdani S, Sahab-Negah S. Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther 2021. [PMID: 34694949 DOI: 10.1080/14787210.2022.1997587] [Reference Citation Analysis]
3 Chan HT, Chao CM, Lai CC. Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: A meta-analysis. J Infect 2021;82:e34-5. [PMID: 33373651 DOI: 10.1016/j.jinf.2020.12.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Mongia A, Saha SK, Chouzenoux E, Majumdar A. A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials. Sci Rep 2021;11:9047. [PMID: 33907209 DOI: 10.1038/s41598-021-88153-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Yang Y, Cui X, Wei H, Guo C, Zhang Y. Potential Anti-Coronavirus Agents and the Pharmacologic Mechanisms. Drug Des Devel Ther 2021;15:1213-23. [PMID: 33762818 DOI: 10.2147/DDDT.S293216] [Reference Citation Analysis]
6 Aherfi S, Pradines B, Devaux C, Honore S, Colson P, Scola B, Raoult D. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. Future Microbiol 2021;16:1341-70. [PMID: 34755538 DOI: 10.2217/fmb-2021-0019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Españo E, Kim D, Kim J, Park SK, Kim JK. COVID-19 Antiviral and Treatment Candidates: Current Status. Immune Netw 2021;21:e7. [PMID: 33728100 DOI: 10.4110/in.2021.21.e7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Itaya T, Isobe Y, Suzuki S, Koike K, Nishigaki M, Yamamoto Y. The Fragility of Statistically Significant Results in Randomized Clinical Trials for COVID-19. JAMA Netw Open 2022;5:e222973. [PMID: 35302631 DOI: 10.1001/jamanetworkopen.2022.2973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lai CC, Chao CM, Hsueh PR. Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials. J Microbiol Immunol Infect 2021:S1684-1182(21)00135-3. [PMID: 34253490 DOI: 10.1016/j.jmii.2021.05.011] [Reference Citation Analysis]
10 El-Bendary M, Abd-Elsalam S, Elbaz T, El-Akel W, Cordie A, Elhadidy T, Elalfy H, Farid K, Elegezy M, El-Badrawy A, Neamatallah M, Abd Elghafar M, Salama M, AbdAllah M, Essam M, El-Shazly M, Esmat G. Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study. Expert Rev Anti Infect Ther 2021;:1-5. [PMID: 34225541 DOI: 10.1080/14787210.2021.1950532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Aslan AT, Akova M. Current status of therapeutic alternatives for COVID-19: A narrative review. Infez Med 2021;29:312-27. [PMID: 35146336 DOI: 10.53854/liim-2903-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Zhao L, Li S, Zhong W. Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review. Front Pharmacol 2022;13:840639. [DOI: 10.3389/fphar.2022.840639] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
13 Sezer A, Halilović-Alihodžić M, Vanwieren AR, Smajkan A, Karić A, Djedović H, Šutković J. A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives. J Genet Eng Biotechnol 2022;20:78. [PMID: 35608704 DOI: 10.1186/s43141-022-00353-0] [Reference Citation Analysis]
14 Zein AFMZ, Sulistiyana CS, Raffaello WM, Wibowo A, Pranata R. Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment. Postgrad Med J 2021:postgradmedj-2021-140287. [PMID: 34103373 DOI: 10.1136/postgradmedj-2021-140287] [Reference Citation Analysis]
15 Cavanna L, Citterio C. Randomised clinical trials on outpatient treatment of SARS-COV-2 infection: Light and shadows. Int J Clin Pract 2021;75:e14896. [PMID: 34965649 DOI: 10.1111/ijcp.14896] [Reference Citation Analysis]
16 Khan S, Attar F, Bloukh SH, Sharifi M, Nabi F, Bai Q, Khan RH, Falahati M. A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase. Int J Biol Macromol 2021;181:605-11. [PMID: 33766591 DOI: 10.1016/j.ijbiomac.2021.03.112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Asili P, Mirahmad M, Tabatabaei-Malazy O, Manayi A, Haghighat E, Mahdavi M, Larijani B. Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review. Daru 2021;29:449-67. [PMID: 34762250 DOI: 10.1007/s40199-021-00422-8] [Reference Citation Analysis]
18 Mobarak S, Salasi M, Hormati A, Khodadadi J, Ziaee M, Abedi F, Ebrahimzadeh A, Azarkar Z, Mansour-Ghanaei F, Joukar F, Yeganeh S, Yaghubi Kalurazi T, Naghipour M, Mehrabi Z, Bahadori AR, Yaghoubi S, Moslemi R, Abbaspour Kasgari H, Fakheri H, Moghimi M, Shabani AM, Nekoukar Z, Babamahmoodi F, Davoudi Badabi AR, Davoodi L, Hassaniazad M, Barahimi E, Tousi A, Sadeghi A, Hosamirudsari H, Ali Asgari A, Abdollahi M, Anushiravani A, Shabani M, Shokouhi S, Khajavirad N, Salehi M, Dehghan Manshadi SA, Mousavi H, Zolfaghari F, Azimi E, Zeinali A, Akbarpour E, Merat D, Eslami G, Mousaviasl S, Sayar S, Radmanesh E, Ebrahimzadeh M, Arizavi Z, Jelvay S, Salmanzadeh S, Esmaeilian H, Mobarak M, Karimi J, Poormontaseri Z, Hasooni Bahrini N, Bonyadi A, Dehghani F, Mirzaei H, Noori Jangi M, Pourmasoomi H, Rezaie Keikhaie L, Afshari M, Nateghi Baygi A, Nateghi Baygi H, Levi J, McCann K, Wentzel H, Simmons B, Hill A, Merat S. Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER). J Antimicrob Chemother 2021:dkab433. [PMID: 34849957 DOI: 10.1093/jac/dkab433] [Reference Citation Analysis]
19 Gil Martínez V, Avedillo Salas A, Santander Ballestín S. Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review. Pharmaceuticals (Basel) 2021;14:736. [PMID: 34451833 DOI: 10.3390/ph14080736] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Medhat MA, El-kassas M, Karam-allah H, Al Shafie A, Abd-elsalam S, Moustafa E, Hassany SM, Salama M, Abd Elghafar MS, Sayed H, Badr M, Kamal DT, Shamseldeen A, Ossimi A, Moaz I, El-deen Esmael H, Ezz Eldin AM, Ezzat S, Abdelghaffar H, Abdelghaffar K. Sofosbuvir/Ledipasvir in Combination or Nitazoxanide Alone are Safe and Efficient Treatments for COVID-19 Infection: A Randomized Controlled Trial for Repurposing antivirals. Arab Journal of Gastroenterology 2022. [DOI: 10.1016/j.ajg.2022.04.005] [Reference Citation Analysis]
21 Ramakrishnan S, Nicolau DV Jr, Langford B, Mahdi M, Jeffers H, Mwasuku C, Krassowska K, Fox R, Binnian I, Glover V, Bright S, Butler C, Cane JL, Halner A, Matthews PC, Donnelly LE, Simpson JL, Baker JR, Fadai NT, Peterson S, Bengtsson T, Barnes PJ, Russell REK, Bafadhel M. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med 2021;9:763-72. [PMID: 33844996 DOI: 10.1016/S2213-2600(21)00160-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 36.0] [Reference Citation Analysis]
22 Ashour L. Roles of the ACE/Ang II/AT1R pathway, cytokine release, and alteration of tight junctions in COVID-19 pathogenesis. Tissue Barriers 2022;:2090792. [PMID: 35726726 DOI: 10.1080/21688370.2022.2090792] [Reference Citation Analysis]
23 Chen C, Weng T, Chen Y, Kao JH, Chao C. Clinical efficacy of sofosbuvir/daclatasvir in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Expert Review of Clinical Pharmacology. [DOI: 10.1080/17512433.2022.2103539] [Reference Citation Analysis]
24 Abbass S, Kamal E, Salama M, Salman T, Sabry A, Abdel-Razek W, Helmy S, Abdelgwad A, Sakr N, Elgazzar M, Einar M, Farouk M, Saif M, Shehab I, El-Hosieny E, Mansour M, Mahdi D, Tharwa ES, Salah M, Elrouby O, Waked I. Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial. J Med Virol 2021. [PMID: 34379337 DOI: 10.1002/jmv.27264] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Vegivinti CTR, Evanson KW, Lyons H, Akosman I, Barrett A, Hardy N, Kane B, Keesari PR, Pulakurthi YS, Sheffels E, Balasubramanian P, Chibbar R, Chittajallu S, Cowie K, Karon J, Siegel L, Tarchand R, Zinn C, Gupta N, Kallmes KM, Saravu K, Touchette J. Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials. BMC Infect Dis 2022;22:107. [PMID: 35100985 DOI: 10.1186/s12879-022-07068-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
26 Davoodi L, Jafarpour H, Oladi Z, Zakariaei Z, Tabarestani M, Ahmadi BM, Razavi A, Hessami A. Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial. Int J Cardiol Heart Vasc 2021;36:100875. [PMID: 34541293 DOI: 10.1016/j.ijcha.2021.100875] [Reference Citation Analysis]